Under one in 10 individuals eligible to benefit from obesity jabs including Wegovy are able to get them, states the WHO as it releases its initial guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our new guidance recognises that excess weight is a chronic disease that can be treated with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to widespread access to the jabs that can assist patients in reducing considerable body mass, explains the body.
Skinny Jab Shortage
Even in the current most favorable outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – less than 10% of the global need, according to the WHO.
The advice urges countries and companies to expand availability, via strategies like licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs mimick a natural hormone to reduce digestion speed, curb appetite and boost satiety so users consume fewer calories.
People commonly start to lose weight within a few weeks of beginning the regular doses.
Evidence suggests people may regain a significant portion within a year of discontinuing the medication, as their usual appetite come back.
To be overweight or obese raises your chance for developing diseases, including diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns individuals in every country and was linked to millions of deaths worldwide in 2024, as per the WHO.
